Business context and reporting period
Filing identity: The request metadata names Axe Compute Inc., but the supplied Form 10-Q is for Predictive Oncology Inc. (Nasdaq: POAI). Confirm the filing and issuer before relying on this summary.
The unaudited report covers the three months ended March 31, 2023, compared with the three months ended March 31, 2022. Predictive Oncology applies AI and a biobank of more than 150,000 tumor samples to oncology drug development; it also operates biologics research services and the STREAMWAY medical fluid-management product business. Effective January 1, 2023, it reported Pittsburgh, Birmingham, and Eagan segments and said it would focus resources on AI-enabled cancer therapy development.
Financial results and liquidity
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Revenue | $239,895 | $314,568; down $74,673 |
| Gross profit / margin | $119,756 / approximately 50% | $205,125 / approximately 65% |
| Operating loss | $3,464,983 | $3,414,064 |
| Net loss | $3,421,802 | $3,370,715 |
| Basic and diluted loss per share | $0.86 | $1.02 |
| Net cash used in operating activities | $3,427,761 | $3,093,696 |
| Cash and cash equivalents at period end | $18,597,119 | $22,071,523 at December 31, 2022 |
Investing activities used $46,643 in cash; financing activities provided no cash in Q1 2023. The company reported no outstanding debt at March 31, 2023. Total liabilities were $6,507,194, including $3,024,523 of operating lease liabilities. Total assets were $25,061,579 and stockholders’ equity was $18,554,385.
Material changes versus the prior comparable period
- Revenue fell by $74,673. Eagan contributed $215,619, or about 90% of revenue; the company sold no net STREAMWAY systems in Q1 2023, compared with three in Q1 2022.
- Gross margin declined to approximately 50% from 65%, which management attributed mainly to sales mix and lower margins on repair and maintenance contracts.
- Net loss increased by $51,087, while operating cash use increased by $334,065.
- General and administrative expense declined by $87,667, primarily after closure of the TumorGenesis and zPREDICTA offices; sales and marketing expense rose by $65,770, mainly due to added marketing and business-development staff.
- Lease right-of-use assets and liabilities increased after the company entered two approximately five-year Pittsburgh leases in January 2023; it recorded $2,922,365 of related right-of-use assets and lease liabilities.
Outlook, risks, contingencies, and unusual items
Management stated that existing capital resources were expected to support its operating plan for the next 12 months and beyond after issuance of the statements. It also said it may seek additional debt, equity, asset-sale proceeds, or other financing, and could implement cost savings if results differ from plan. No quantified revenue, profit, or cash-flow guidance was provided.
- The company has a history of losses and negative operating cash flow; it reported an accumulated deficit of $157,199,718. Management cited continued cash burn, financing needs and potentially dilutive or onerous financing terms as risks.
- Disclosure controls and procedures were reported as ineffective at March 31, 2023 because of a previously identified material weakness: inadequate accounting resources and expertise for complex transactions. The company reported hiring additional accounting resources and conducting remediation testing, but had not yet concluded the weakness was fully remediated.
- Management described continuing COVID-19-related supply-chain, staffing, production, and demand disruptions, with uncertain effects on operations and liquidity.
- After quarter-end, the company completed a one-for-twenty reverse stock split, effective for trading April 24, 2023. It also reported that Series F preferred shares issued in connection with the vote were redeemed on April 19, 2023, and that Nasdaq notified it on May 8, 2023 that it had regained compliance with the minimum bid-price requirement.
- The filing reported no pending legal proceedings that management believed were likely to have a material adverse effect. It disclosed no material contingency amount.
Important facts for investors to verify
- Confirm that Predictive Oncology Inc., rather than Axe Compute Inc., is the issuer relevant to the requested review.
- Assess whether the stated cash resources remain adequate given operating cash use of $3.43 million during the quarter, and whether management’s 12-month liquidity outlook remains current.
- Track revenue, STREAMWAY unit sales, and segment performance—especially whether the AI-focused Pittsburgh business can grow materially from its reported revenue base.
- Review remediation progress and subsequent testing for the material weakness in internal control over financial reporting.
- Confirm the effects of the reverse split on share counts, outstanding warrants and equity awards, and Nasdaq listing status.